LEO Innovation Lab CEO wins eyeforpharma Customer Innovator Award

LEO Innovation LabLEO Innovation Lab is proud to announce that our CEO Kristian Hart-Hansen has won the eyeforpharma Customer Innovator Award. Kristian has spearheaded the growth of the LEO Innovation Lab since it's conception in 2015 with just six team members, to a thriving incubator of over 80 people and 15 projects today. The lab was established by LEO Pharma as an independent initiative to focus on using digital innovation to help individuals manage chronic skin conditions.

The eyeforpharma awards celebrate innovative approaches to driving value for patients in the pharmaceutical industry, and aim to shine a light on individuals that are striving for long-term results. The awards' vision is "to make the pharmaceutical industry more open and valued... and to shine a light on where pharma does well, to inspire others into similar or better action". Moreover, the eyeforpharma Awards celebrate "those who aren't just chasing higher short-term profits, but who are investing in better customer innovation, value and outcomes leading to longer-term success."

The LEO Innovation Lab was born out of the desire to create a patient-focussed approach to managing chronic skin conditions. The lab aims to grow digital solutions for people living with psoriasis or other chronic skin conditionsand bring them to market. Nurturing digital innovation in an agile start-up environment has led to some groundbreaking success stories, including eyeforpharma finalists TREAT, the nutrition coaching service for sufferers of chronic skin conditions, and PsoHappy, creator of the world’s first study on happiness and psoriasis.

Kristian has built up an international team from a wide range of disciplines to better understand the digital behaviour of psoriasis patients and how to meet their needs. Under his leadership, the LEO Innovation Lab team has grown into a unique growth setup, with a flat management hierarchy and a progressive approach to resource allocation. This ensures that the patient's needs can be easily prioritised and valuable insights are being surfaced every day.

"I'm thrilled to be accepting this award on behalf of the LEO Innovation Lab team. Since we began, we've done our best to build a streamlined working model that focusses on understanding more about the patients we're trying to help. I truly believe the things we're learning will be beneficial not only for our own projects, but to the pharmaceutical industry as a whole as time goes on. TREAT and PsoHappy are just two examples of what the LEO Innovation Lab can do, and I look forward to introducing more groundbreaking projects very soon," mentioned Kristian Hart-Hansen, CEO, LEO Innovation Lab.

For further information, please visit:
https://leoinnovationlab.com

About LEO Innovation Lab
LEO Innovation Lab is an organisation which, instead of developing pharmaceutical treatments, looks at all the aspects of everyday life that can affect a person who has a skin condition and develops digital solutions to support them.

LEO Innovation Lab has been established as a separate entity by LEO Pharma as part of a long-term strategic decision to focus on patient needs.

As LEO Pharma is owned entirely by the LEO Foundation and has no shareholders, its profits are reinvested in developing new solutions to support the overall mission: To help people achieve healthy skin. This unique ownership structure has made it possible to establish LEO Innovation Lab with a goal of making a difference to people living with a skin condition.

About eyeforpharma
Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry’s health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the center.

Most Popular Now

Novartis confirms 5 year data for first and only f…

Novartis, a global leader in Immunology & Dermatology, confirmed today positive 5 year efficacy and safety results for Cosentyx® from a Phase III long-term extension stud...

Researchers develop microneedle patch for flu vacc…

A National Institutes of Health-funded study led by a team at the Georgia Institute of Technology and Emory University has shown that an influenza vaccine can produce rob...

Jardiance® (empagliflozin) analysis reinforces est…

An analysis of pooled safety data from 15 studies plus 4 extension studies involving more than 12,500 adults with type 2 diabetes demonstrated treatment with Jardiance® (...

Alzheimer's and Parkinson's spurred by same enzyme

Alzheimer's disease and Parkinson's disease are not the same. They affect different regions of the brain and have distinct genetic and environmental risk factors. But at ...

Researchers publish new findings on influence of h…

Poor diet is associated with 80% of colorectal cancer cases, but the exact pathways by which diet leads to cancer are not known. In a newly published study, Cleveland Cli...

Merck awards €1.25 million to research projects th…

Merck, a leading science and technology company, today announced its commitment to award €1.25 million to research projects in the field of fertility, supporting the adva...

FDA tackles drug competition to improve patient ac…

Today, the U.S. Food and Drug Administration is taking two new, important steps to increase competition in the market for prescription drugs and facilitate entry of lower...

Trials show unique stem cells a potential asthma t…

A study led by scientists at Monash University has shown that a new therapy developed through stem cell technology holds promise as a treatment for chronic asthma. The Mo...

Roche acquires mySugr to form a leading open platf…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and mySugr have signed an agreement under which Roche acquired all shares of mySugr GmbH. Counting more than one million users globally...

Older Americans don't get - or seek - enough help …

The majority of Americans over age 50 take two or more prescription medicines to prevent or treat health problems, and many of them say the cost weighs on their budget, a...

Novartis CAR-T cell therapy CTL019 unanimously (10…

Novartis announced today that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) unanimously (10-0) recommended approval of CTL019 (tisag...

New brain cancer drug targets revealed

Researchers from Case Western Reserve University School of Medicine and The Cleveland Clinic designed a way to screen brain tumor cells and identify potential drug target...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]